相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
Michael J. Lipinski et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Michel Farnier et al.
ATHEROSCLEROSIS (2016)
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
John J. P. Kastelein et al.
EUROPEAN HEART JOURNAL (2016)
Amgen's PCSK9 patents upheld
NATURE BIOTECHNOLOGY (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study
Toru Miyoshi et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2015)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
Eliano Pio Navarese et al.
ANNALS OF INTERNAL MEDICINE (2015)
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies
Angela Pirillo et al.
ATHEROSCLEROSIS (2015)
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
Eveline P. van Poelgeest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population
Christel H. Kamani et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Understanding PCSK9 and anti-PCSK9 therapies
James M. McKenney
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
Michael J. Koren et al.
POSTGRADUATE MEDICINE (2015)
A cholesterol-lowering VLP vaccine that targets PCSK9
Erin Crossey et al.
VACCINE (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
TRIAL EVALUATING EVOLOCUMAB, A PCSK9 ANTIBODY, IN PATIENTS WITH HOMOZYGOUS FH (TESLA): RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
F. Raal et al.
ATHEROSCLEROSIS (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
Marianne Abifadel et al.
CURRENT ATHEROSCLEROSIS REPORTS (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
Evan A. Stein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Frederick J. Raal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
Majambu Mbikay et al.
FEBS OPEN BIO (2014)
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
Tracy Mitchell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Giuseppe Derosa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
EFFECTS OF RG7652, A FULLY HUMAN MAB AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ON LDL-C: A PHASE I, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE STUDY
Whittemore Tingley et al.
HEART (2013)
The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Hui Dong et al.
PLANTA MEDICA (2013)
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
Heiner K. Berthold et al.
PLOS ONE (2013)
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
Marianne Abifadel et al.
ATHEROSCLEROSIS (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
Iris Postmus et al.
JOURNAL OF LIPID RESEARCH (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
Michelle Melone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
Livia Pisciotta et al.
LIPIDS IN HEALTH AND DISEASE (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Nabil G. Seidah et al.
PLOS ONE (2012)
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogen Diet-induced Hypercholesterolemic Mice
Tsuyoshi Yamamoto et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
Tohru Noguchi et al.
ATHEROSCLEROSIS (2011)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Marianne Abifadel et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Jason S. Troutt et al.
JOURNAL OF LIPID RESEARCH (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
F. Affuso et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
Lena Persson et al.
ENDOCRINOLOGY (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
Hai Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
Familial hypercholesterolaemia in Portugal
M. Bourbon et al.
ATHEROSCLEROSIS (2008)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
Mary Cabell Jonas et al.
EMBO REPORTS (2008)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Cedric Langhi et al.
FEBS LETTERS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
J. Cameron et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Combination of simvastatin with berberine improves the lipid-lowering efficacy
Wei-Jia Kong et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence
Aaron R. Folsom et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
J Cameron et al.
HUMAN MOLECULAR GENETICS (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia
XM Sun et al.
HUMAN MOLECULAR GENETICS (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
WJ Kong et al.
NATURE MEDICINE (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
KN Maxwell et al.
JOURNAL OF LIPID RESEARCH (2003)
Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred
SC Hunt et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)